<DOC>
	<DOCNO>NCT02261129</DOCNO>
	<brief_summary>Study demonstrate bioequivalence telmisartan 80 mg film-coated tablet vs. two tablet telmisartan 40 mg conventional tablet</brief_summary>
	<brief_title>Bioequivalence Telmisartan Film-coated Tablet Compared With Two Tablets Conventional Telmisartan Tablet Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<criteria>1 . Healthy Japanese male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( Blood pressure , pulse rate , body temperature ) , 12lead ECG , clinical laboratory test 1.1 No finding deviate normal clinical relevance 1.2 No evidence clinically relevant concomitant disease 2 . Age ≥20 ≤35 year 3 . Body weight≥50kg 4 . Body Mass Index ≥18.0 ≤25.0 kg/m2 5 . Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation 1 . Any finding medical examination ( include blood pressure , pulse rate , body temperature , ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . Chronic relevant acute infection 6 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 7 . Any clinical relevant finding laboratory test deviate normal 8 . Positive result either hepatitis B antigen , anti hepatitis C virus antibody , syphilitic test human immunodeficiency virus ( HIV ) test 9 . History surgery gastrointestinal tract ( except appendectomy ) 10 . History relevant orthostatic hypotension ( mean stand systolic blood pressure ( SBP ) vary ≥20 mmHg mean supine SBP mean stand diastolic blood pressure ( DBP ) vary ≥10 mmHg mean supine DBP ) , faint spell blackouts 11 . History hepatic dysfunction ( e.g . biliary cirrhosis , cholestasis ) 12 . History serious renal dysfunction 13 . History bilateral renal artery stenosis renal artery stenosis solitary kidney 14 . History cerebrovascular disorder 15 . History hyperkalemia 16 . Known hypersensitivity component telmisartan formulation , angiotensin II receptor blocker 17 . Intake drug long halflife ( ≥24 hour ) within least one month le 10 halflives respective drug administration investigational product 18 . Use drug within 10 day administration investigational product trial 19 . Participation another trial investigational drug within four month administration investigational product trial 20 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 21 . Alcohol abuse 22 . Drug abuse 23 . Blood donation ( 100 mL ) within four week administration investigational product 24 . Excessive physical activity within one week administration investigational product trial 25 . Intake alcohol within 2 day prior administration 26 . Inability comply dietary regimen study centre 27 . Inability refrain smoke trial day 28 . Any clinical condition investigator subinvestigator judge subject ineligible study participation</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>